InnerCap Tech Inc v. Nouri Life Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: InnerCap Technologies, Inc. (Florida)
  • Defendant: Nouri Life, Inc. (Delaware)
  • Plaintiff's Counsel: Farnan LLP
• Case Identification: InnerCap Technologies, Inc. v. Nouri Life, Inc., 1:26-cv-00903, D. Del., 07/24/2026
• Venue Allegations: Venue is alleged to be proper in the District of Delaware because the Defendant is a Delaware corporation and therefore resides in the district.
• Core Dispute: Plaintiff alleges that Defendant's line of capsule-in-capsule probiotic products infringes a patent related to multi-compartment capsular drug delivery systems.
• Technical Context: The technology addresses the challenge of combining chemically or physically incompatible ingredients, such as liquids and solids, into a single oral dosage form.
• Key Procedural History: The lawsuit seeks damages for infringement that occurred prior to the patent's expiration on June 11, 2026. The complaint notes that the patent-in-suit was the subject of a supplemental examination where the U.S. Patent and Trademark Office concluded in 2025 that eleven prior art references did not raise a substantial new question of patentability regarding several claims, including the representative claim asserted in this case.

Case Timeline

Date	Event
2002-04-10	'612 Patent Priority Date
2010-03-02	'612 Patent Issue Date
2023-02-23	Plaintiff alleges it put Defendant on notice of infringement
2025-10-15	Request for supplemental examination of the '612 Patent filed
2025-10-31	USPTO finds no substantial new question of patentability in supplemental examination
2025-12-14	Plaintiff's counsel sends second letter to Defendant regarding infringement
2026-06-11	'612 Patent Expiration Date
2026-07-24	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 7,670,612 - Multi-phase, multi-compartment capsular delivery apparatus and methods for using same

The Invention Explained

• Problem Addressed: The patent addresses the difficulty of creating a single dosage form that contains multiple active ingredients when those ingredients are chemically incompatible, have different physical states (e.g., liquid and solid), or require different release times within the body Compl. ¶13 '612 Patent, col. 5:1-21
• The Patented Solution: The invention provides a multi-compartment capsule, most notably a "capsule-in-capsule" design, where an inner capsule is placed inside an outer capsule '612 Patent, fig. 10 This structure physically separates the ingredients, preventing unwanted chemical reactions and allowing for staged release, where the outer capsule can dissolve first (immediate release) and the inner capsule can dissolve later (time-delayed release) '612 Patent, abstract '612 Patent, col. 1:41-51
• Technical Importance: This technology enables the formulation of complex combination products that could not otherwise be co-formulated, offering improved patient convenience and potentially new therapeutic applications by delivering multiple agents in a single dose Compl. ¶13

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 33 Compl. ¶21
• The essential elements of independent claim 33 are:
  • A multi-compartment capsule,
  • Comprising a first receiving chamber containing at least one oil in immediate release form,
  • And a second receiving chamber that contains only solid ingredients, includes at least one solid active ingredient, and is formulated for time-delayed dissolution and release,
  • Wherein the ingredients of the first chamber are different from the ingredients of the second chamber,
  • Wherein the second chamber is enveloped by the first chamber,
  • And wherein the multi-compartment capsule is a hard shell capsule.
• The complaint reserves the right to assert other claims, including at least claims 5, 6, 9, 10, 24, and 65 Compl. ¶64

III. The Accused Instrumentality

Product Identification

The Accused Instrumentality is Defendant's various lines of capsule-in-capsule probiotic products, including Hormone Balance Probiotic, Digestive Support Probiotic, and others Compl. ¶3 The Nouri Digestive Support Probiotic is identified as the representative accused product for the infringement analysis Compl. ¶24

Functionality and Market Context

The Accused Products are alleged to use a capsule-in-capsule design where an outer capsule contains a plant-based omega oil blend and an inner capsule contains solid probiotic ingredients Compl. ¶¶32, 42, 53 This structure is marketed as delivering probiotics "twice as effectively" by protecting them from stomach acid, allowing for a delayed release in the gut Compl. ¶48 Compl. p. 6, Fig. 1 The complaint provides an annotated image from the product's packaging highlighting the separate ingredients in the inner and outer capsules. Compl. p. 12, Fig. 8

IV. Analysis of Infringement Allegations

'612 Patent Infringement Allegations

Claim Element (from Independent Claim 33)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A multi-compartment capsule, comprising:	The Accused Products are described and marketed as having a "Capsule-in-Capsule" structure.	¶29	col. 7:51-54
a first receiving chamber comprising at least one oil in immediate release form; and	The outer capsule ("first receiving chamber") is alleged to contain a "plant-based omega oil" blend formulated for immediate release.	¶32	col. 9:1-10
a second receiving chamber containing only solid ingredients and	The inner capsule ("second receiving chamber") is alleged to contain only solid ingredients in a dry powder state, as shown in deconstruction photographs.	¶¶38-39	col. 29:10-14
comprising at least one active ingredient in a solid state and	The inner capsule's solid powder is alleged to contain active probiotic ingredients, including Lactobacillus plantarum.	¶42	col. 29:10-14
formulated in a manner allowing for a time-delayed dissolution and release of said solid active ingredient,	The inner capsule is enveloped by the outer capsule, which allegedly causes its release to be delayed until after the outer capsule dissolves.	¶¶47-49	col. 11:47-54
wherein the ingredients contained in said first receiving chamber are different from the ingredients of said second receiving chamber,	The outer chamber contains an oil blend, while the inner chamber contains dry probiotic ingredients, which are different.	¶53	col. 5:1-14
and wherein said second receiving chamber is enveloped by said first receiving chamber,	Photographs are provided showing the inner capsule ("second receiving chamber") contained within and enveloped by the outer capsule ("first receiving chamber").	¶57	col. 94:23-24
and wherein the multi-compartment capsule is a hard shell capsule.	The capsule is made of "vegetable cellulose," which the complaint alleges constitutes a "hard shell capsule."	¶¶61-62	col. 94:52-54

Identified Points of Contention

• Scope Questions: The infringement analysis may turn on the construction of "hard shell capsule". The complaint alleges that the accused product's "vegetable cellulose" capsule meets this limitation Compl. ¶62 A point of contention could be whether "hard shell capsule" as understood in the patent is limited to traditional two-piece gelatin capsules or if it is broad enough to cover the specific type of vegetable cellulose capsule used by the Defendant.
• Technical Questions: A key question is whether the accused product meets the "formulated in a manner allowing for a time-delayed dissolution" limitation. The complaint's theory is that the physical nesting of the inner capsule inside the outer capsule inherently creates a time delay Compl. ¶48 The analysis may question whether this structural arrangement alone satisfies the "formulated in a manner" requirement, or if the claim demands a specific coating or material property of the inner capsule itself to achieve the time delay. The complaint provides photographs of the deconstructed capsule, which will serve as central evidence for this analysis. Compl. p. 9, Figs. 4, 5, & 6 The complaint also presents images of the fully assembled capsule to illustrate the nested structure. Compl. p. 13, Figs. 9 & 10

V. Key Claim Terms for Construction

The Term: "hard shell capsule"

• Context and Importance: This term is critical because infringement of claim 33 depends on whether the accused product, made of "vegetable cellulose," qualifies as a "hard shell capsule" (Compl. ¶61; Compl. ¶62). Practitioners may focus on this term because its definition will determine if the patent's scope covers modern capsule materials beyond the traditional gelatin standard.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification lists materials for capsule walls, including "gelatin (animal-based product), starch, hydrophillic polymer or hydroxypropyl methyl-cellulose (HPMC)" '612 Patent, col. 2:27-34 HPMC is a common material for modern hard-shell vegetable capsules, which may support construing the term to include materials other than just gelatin.
  • Evidence for a Narrower Interpretation: The background section of the patent draws a distinction between "hard gelatin capsules" and "soft elastic capsules" '612 Patent, col. 2:12-62 A party could argue that "hard shell capsule" should be limited to the conventional two-piece telescoping gelatin capsules that were the standard at the time, potentially excluding the accused product's specific construction.

The Term: "formulated in a manner allowing for a time-delayed dissolution"

• Context and Importance: The plaintiff's infringement theory relies on the physical placement of the inner capsule within the outer one as satisfying this limitation Compl. ¶¶48-49 Practitioners may focus on this term because the case could turn on whether "formulated" refers to the entire product's assembly or requires a specific feature of the inner capsule component itself.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent discusses achieving different release rates through various means, including the overall structure of the multi-compartment system '612 Patent, col. 44:30-53 This may support an argument that the "formulation" of the final product as a capsule-in-capsule system is what allows for the time delay.
  • Evidence for a Narrower Interpretation: The patent repeatedly mentions "time-release coatings" as a mechanism for delaying dissolution ('612 Patent, col. 11:47-54). The claim element modifies the "second receiving chamber." This could support an argument that the inner capsule itself must be "formulated" with a specific feature, such as a coating, to meet this limitation, and that merely being inside another capsule is insufficient.

VI. Other Allegations

Indirect Infringement

The complaint focuses on allegations of direct infringement by making, selling, and offering to sell the Accused Products and does not plead specific facts to support a standalone claim for indirect infringement Compl. ¶20

Willful Infringement

The complaint alleges that Defendant's infringement was willful Compl. ¶66 The asserted basis for willfulness is pre-suit knowledge of the '612 Patent. The complaint alleges that Plaintiff put Defendant on notice via a letter dated February 23, 2023, and sent a follow-up letter on December 14, 2025, but that Defendant continued its infringing activities up to and through the patent's expiration date Compl. ¶¶67-72

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of claim construction: does the term "hard shell capsule", which originates in an era dominated by gelatin, extend to cover the accused product's modern "vegetable cellulose" capsule, or is its meaning confined to the more traditional material and structure?
• A second key question will be one of infringement and technical scope: is the claim limitation requiring the inner capsule to be "formulated in a manner allowing for a time-delayed dissolution" met simply by the act of nesting it inside an outer capsule, or does the language require an intrinsic property of the inner capsule itself, such as a specific coating or material composition, that the complaint does not explicitly allege?
• A final question for the court will be one of willfulness: assuming infringement is found, do the alleged notice letters from 2023 and 2025, combined with the outcome of the 2025 supplemental examination, establish that Defendant's continued infringement was objectively reckless, thereby justifying enhanced damages?